Establishment Labs Holdings Inc. Stock price

Equities

ESTA

VGG312491084

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 03:40:39 2024-03-28 pm EDT 5-day change 1st Jan Change
50.82 USD +0.12% Intraday chart for Establishment Labs Holdings Inc. +4.30% +96.76%
Sales 2024 * 180M Sales 2025 * 247M Capitalization 1.38B
Net income 2024 * -47M Net income 2025 * -17M EV / Sales 2024 * 8.69 x
Net Debt 2024 * 187M Net Debt 2025 * 168M EV / Sales 2025 * 6.27 x
P/E ratio 2024 *
-29.6 x
P/E ratio 2025 *
-80.8 x
Employees 908
Yield 2024 *
-
Yield 2025 *
-
Free-Float 84.77%
More Fundamentals * Assessed data
Dynamic Chart
TD Cowen Adjusts Establishment Labs Price Target to $60 From $50, Maintains Outperform Rating MT
Transcript : Establishment Labs Holdings Inc. Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 02:30 PM
Transcript : Establishment Labs Holdings Inc., Q4 2023 Earnings Call, Feb 28, 2024
Establishment Labs Holdings Inc. Provides Revenue Guidance for the Year 2024 CI
Establishment Labs Holdings Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Earnings Flash (ESTA) ESTABLISHMENT LABS HOLDINGS Reports Q4 Revenue $31.6M, vs. Street Est of $31.6M MT
Establishment Labs Announces Amended Credit Facility with Oaktree CI
Establishment Labs Holdings Inc. announced that it has received $49.999102 million in funding CI
Transcript : Establishment Labs Holdings Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 02:15 PM
Establishment Labs Launches $50 Million Private Placement; Reports Q4, 2023 Preliminary Revenue; Shares Rise 7% MT
Establishment Labs Holdings Inc. announced that it expects to receive $50 million in funding CI
Establishment Labs Holdings Inc. Announces First U.S. Commercial Procedure with Motiva Flora Tissue Expander CI
B. Riley Lowers Establishment Labs Holdings' PT to $50 From $95 After Q3 Topline Miss, Notes Lower Multiple; Maintains Buy Rating MT
Establishment Labs Shares Plunge After Q3 Misses, 2023 Revenue Guidance Cut MT
Transcript : Establishment Labs Holdings Inc., Q3 2023 Earnings Call, Nov 07, 2023
More news
1 day+2.13%
1 week-0.55%
Current month+11.12%
1 month+27.89%
3 months+100.39%
6 months+2.03%
Current year+96.06%
More quotes
1 week
46.78
Extreme 46.78
50.82
1 month
43.06
Extreme 43.055
51.99
Current year
24.42
Extreme 24.42
51.99
1 year
16.96
Extreme 16.96
79.88
3 years
16.96
Extreme 16.96
93.80
5 years
7.56
Extreme 7.56
93.80
10 years
7.56
Extreme 7.56
93.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 12-12-31
Director of Finance/CFO 54 21-02-23
Chief Tech/Sci/R&D Officer 44 08-12-31
Members of the board TitleAgeSince
Director/Board Member 75 17-11-30
Director/Board Member 72 15-07-31
Chairman 46 15-08-31
More insiders
Date Price Change Volume
24-03-28 50.87 +0.22% 234 311
24-03-27 50.76 +2.13% 282,003
24-03-26 49.7 +4.06% 383,848
24-03-25 47.76 +0.13% 291,125
24-03-22 47.7 -2.33% 437,702

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Establishment Labs Holdings Inc. is Costa Rica-based medical technology and aesthetics company that is focused on women's health reconstruction market. The Company is engaged in the designing, developing, manufacturing and marketing of product portfolio consisting of silicone-filled breast and body shaping implants. The main activities are conducted at two manufacturing facilities in Costa Rica including Motiva Implants brand sold in over 80 countries globally through a combination of distributors and direct sales to customers.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
50.76 USD
Average target price
54.29 USD
Spread / Average Target
+6.95%
Consensus
  1. Stock
  2. Equities
  3. Stock Establishment Labs Holdings Inc. - Nasdaq